Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DA-19-015

Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R41/R42 - Clinical Trial Optional)

Closed on December 14, 2018.

Posted
September 18, 2018
Close date
December 14, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $447,369 in first-year total cost, median $223,685.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 GXM-A (17)]2

Most frequent institutions

  1. DYNAMICARE HEALTH, INC.1
  2. Q2I, LLC1
Competing awards under RFA-DA-19-015 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Reward-based technology to improve opioid use disorder treatment initiation after an ED visit1R42DA049448-01BOUDREAUX, EDWIN DQ2I, LLC, NH$224,986ZDA1
2019Smartphone-based rewards as a bridge to treatment for naloxone reversal patients1R41DA049390-01DEFULIO, ANTHONYDYNAMICARE HEALTH, INC., MA$222,383ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DA-19-015: Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R41/R42 - Clinical Trial Optional) | ScienceDex | ConductScience